If approved, it would be the first major new drug treatment for Parkinson’s in half a century. Richard Mailman, a University ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical stud ...

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class ...

NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction NMRA-215 demonstrated best-in-class ...

ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics ...

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have published a ...

In combination, two commonly used heart drugs reverse fat accumulation in the liver, a study in animals has shown.

Scientists continue to explore ways we can live longer and ensure those lives are healthier. A new discovery of note in this field comes from experiments in fission yeast (an organism often used for ...

You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters ...

The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...